A Multicenter Phase II Trial of Neoadjuvant JS001, or JS001 in Combination With Chemotherapy in Resectable NSCLC
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Toripalimab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NAJSCR
- 26 Feb 2019 Study design, arms and interventions, trial identification hs been amended.
- 26 Feb 2019 Planned End Date changed from 1 Jul 2023 to 1 Mar 2024.
- 26 Feb 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Mar 2021.